Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex Inc. (ZYXI) is a leader in non-invasive medical technology, specializing in electrotherapy devices, pain management solutions, and advanced patient monitoring systems. This news hub provides investors and industry professionals with essential updates on the company’s latest developments, regulatory milestones, and strategic initiatives.
Access real-time information on Zynex’s FDA clearances, product innovations, and financial performance. Our curated news collection covers earnings reports, partnership announcements, clinical trial outcomes, and market expansion efforts. Stay informed about developments across Zynex Medical’s therapeutic devices, Monitoring Solutions’ cardiac technologies, and Neurodiagnostics’ advancements in neurological care.
This resource is designed for those tracking Zynex’s progress in bringing clinically validated medical devices to market. Discover updates on key focus areas including TENS therapy improvements, laser-based monitoring innovations, and compliance with global medical standards. Bookmark this page for streamlined access to press releases, analyst insights, and objective reporting on Zynex’s role in shaping healthcare technology.
Zynex (NASDAQ: ZYXI) reported Q2 2024 financial results with revenue increasing 11% to $49.9 million. Key highlights include:
- Q2 2024 orders up 20% year-over-year, marking the ninth consecutive quarter of record orders
- Net income of $1.2 million; Diluted EPS $0.04
- Year-to-date cash flow from operations up 20% to $3.2 million
- $2.2 million in share repurchases during Q2
The company revised its 2024 guidance, now expecting revenue growth of approximately 9% compared to 2023. For Q3 2024, Zynex estimates revenue of at least $50 million and Diluted EPS of at least $0.05. The full year 2024 outlook projects net revenue of at least $200 million with Diluted EPS of at least $0.20 per share.
Zynex (NASDAQ: ZYXI), a medical technology company specializing in non-invasive devices for pain management, rehabilitation, and patient monitoring, has scheduled its second quarter 2024 earnings call for Thursday, July 25, 2024, at 4:15 PM Eastern Time. The company will release its financial results for the quarter ended June 30, 2024, prior to the call.
Investors can access the call via phone or webcast. The U.S. & Canada dial-in number is 800-930-7718, while the international number is 646-394-9830. A webcast link will also be available on the company's investor relations website. Participants are advised to join the call 5-10 minutes before the start time.
Zynex (NASDAQ: ZYXI), a leading medical technology firm, has been honored with multiple awards by Top Workplaces and U.S. News & World Report for 2024-2025. The Top Workplaces program recognized Zynex in its 2024 Manufacturing list, adding to its earlier USA and Regional awards, highlighting workplace culture excellence. U.S. News & World Report acknowledged Zynex with three accolades: Best in Pharmaceuticals and Health Products, Best Companies, and Best in the West based on metrics like pay, benefits, work/life balance, job stability, and career opportunities. These recognitions emphasize Zynex's commitment to employee well-being and professional development. CEO Thomas Sandgaard reaffirmed the company's focus on fostering a supportive work environment to drive business success, including order growth and new product approvals.
Zynex (NASDAQ: ZYXI) announced its participation in an analyst-led fireside chat at RBC Capital Markets' 2024 Medical Device Strategy & Innovation Call on June 13, 2024. The discussion will feature Shagun Singh, Medical Supplies & Devices Analyst at RBC Capital Markets, and Thomas Sandgaard, Chairman, President & CEO of Zynex. The event, set for 11:00 AM to 12:00 PM ET, will be available via webcast with registration required. A replay will be accessible for two weeks post-event.
Zynex, Inc. (NASDAQ: ZYXI) will present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024. The presentation will cover the company's non-invasive medical devices for pain management, rehabilitation, and patient monitoring. Dan Moorhead, CFO, will be available for one-on-one meetings. The event will be held at the InterContinental Barclay Hotel in New York, NY, and webcast live.
Zynex, Inc. (NASDAQ: ZYXI) has announced that two of its executives, Anna Lucsok, Chief Operating Officer, and Steve Fox, Vice President of Sales, have been recognized among the Top 25 Medical Device Executives by The Healthcare Technology Report. This recognition showcases the high caliber of talent within Zynex, emphasizing their expertise in managing product portfolios and leading departments.
Zynex, Inc. (NASDAQ: ZYXI) reported Q1 2024 revenue of $46.5 million, a 10% increase. Despite revenue underperformance due to delayed payments from insurers post a cyber incident, Zynex remains confident in its full-year revenue forecast. The company saw a net income of $10,000 and repurchased $13.4 million of common stock. New FDA approvals, product launches, and revenue diversification through therapy products show promising growth prospects for Zynex in 2024.
